These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30480089)

  • 1. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.
    Reschly-Krasowski JM; Krasowski MD
    Acad Pathol; 2018; 5():2374289518811797. PubMed ID: 30480089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
    Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S
    BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.
    Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD
    BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.
    Regester LE; Chmiel JD; Holler JM; Vorce SP; Levine B; Bosy TZ
    J Anal Toxicol; 2015 Mar; 39(2):144-51. PubMed ID: 25492523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction.
    Krasowski MD; Drees D; Morris CS; Maakestad J; Blau JL; Ekins S
    BMC Clin Pathol; 2014; 14():33. PubMed ID: 25071417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS.
    Puzyrenko A; Wang D; Schneider R; Wallace G; Schreiber S; Brandt K; Gunsolus IL
    J Anal Toxicol; 2022 Aug; 46(7):712-718. PubMed ID: 34557900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactivity of commercial immunoassays for screening of new amphetamine designer drugs. A review.
    Nieddu M; Baralla E; Pasciu V; Rimoli MG; Boatto G
    J Pharm Biomed Anal; 2022 Sep; 218():114868. PubMed ID: 35688007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.
    Krasowski MD; Ekins S
    J Cheminform; 2014; 6():22. PubMed ID: 24851137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
    Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
    Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
    Colby JM; Patel PC; Fu DY; Rutherford NJ
    Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays.
    Krasowski MD; Siam MG; Iyer M; Ekins S
    Ther Drug Monit; 2009 Jun; 31(3):337-44. PubMed ID: 19333148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretation and Utility of Drug of Abuse Screening Immunoassays: Insights From Laboratory Drug Testing Proficiency Surveys.
    Krasowski MD; McMillin GA; Melanson SEF; Dizon A; Magnani B; Snozek CLH
    Arch Pathol Lab Med; 2020 Feb; 144(2):177-184. PubMed ID: 31313960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens.
    Ge M; Alabi A; Kelner MJ; Fitzgerald RL; Suhandynata RT
    J Appl Lab Med; 2024 Nov; 9(6):964-976. PubMed ID: 39163145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
    Begeman A; Franssen EJF
    Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays.
    Krasowski MD; Siam MG; Iyer M; Pizon AF; Giannoutsos S; Ekins S
    Clin Chem; 2009 Jun; 55(6):1203-13. PubMed ID: 19342505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records.
    Hughey JJ; Colby JM
    Clin Chem; 2019 Dec; 65(12):1522-1531. PubMed ID: 31578215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forensic drug testing for opiates. IV. Analytical sensitivity, specificity, and accuracy of commercial urine opiate immunoassays.
    Cone EJ; Dickerson S; Paul BD; Mitchell JM
    J Anal Toxicol; 1992; 16(2):72-8. PubMed ID: 1501467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.